Safi Biotherapeutics secures a $4.7 million extension to advance manufactured red blood cells toward its first clinical trial.
Amount Raised
$4.7 Million
Round Type
Grant
CambridgeManufacturingBiotechnologyHealth CareInvestors
Description
Safi Biotherapeutics announced a $4.7 million non-dilutive award extension to fund the final IND-enabling work before its first clinical trial. The funding will support core activities for the company's innovative mRBCs. This product aims to address the ongoing shortage of available blood supply. With this financing, Safi moves closer to a clinical trial submission planned for 2027.
Who to call at Safi Biotherapeutics, and when
A new round usually means Safi Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Safi Biotherapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Safi Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Safi Biotherapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Safi Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Safi Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.